Clinical Trials Logo
  1. Home
  2. Reflux Esophagitis
  3. NCT01008696

An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis

Reflux Esophagitis Clinical Trial

Official title:
Effect of Rabeprazole and Lansoprazole on Reflux Esophagitis in Relation to CYP2C19 Genotype Status: A Prospective, Randomized, Multicenter Study

Clinical Trial Summary

The purpose of this study is to compare the treatment effects of rabeprazole and lansoprazole depending on the genotyping (process of determining the genetic constitution) of CYP2C19 in treating reflux esophagitis (caused by gastroesophageal reflux; deterioration of the protective lining on the inner wall of the lower esophagus); and to evaluate the cure rate of reflux esophagitis on endoscopy (a thin flexible tube with a microscopic camera at the end which is passed down your throat into the esophagus, stomach, and duodenum) after treatment with rabeprazole and lansoprazole.

Clinical Trial Description

This is a prospective (study following participants forward in time), open-label (all people know the identity of the intervention), multi-center (conducted in more than 1 center), randomized (study drug assigned by chance) study in participants with reflux esophagitis. The study will include 4 visits: Visit 1 (Screening period of up to 14 days), Visit 2 (Day 1), Visit 3 (Day 29+3), and Visit 4 (Day 56). After Screening, eligible participants will be analyzed on Visit 2 (Day 1) for symptoms during past week, At visit 3 (Day 29+3) participants will be randomly assigned to 1 of the 2 treatment groups: rabeprazole 20 milligram (mg) or lansoprazole 30 mg group. Participants will receive rabeprazole 20 mg tablet orally once daily for 28 to 56 days or lansoprazole 30 mg capsule orally once daily for 28 to 56 days. A post-study follow-up visit will be conducted only if participant will be affected by any serious adverse event within 30 days after the completion of study drug. Participants will primarily be assessed for the cure rate of reflux esophagitis based on endoscopy of 2 groups. Participants' safety will be monitored throughout the study. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01008696
Study type Interventional
Source Janssen Korea, Ltd., Korea
Contact
Status Completed
Phase Phase 4
Start date May 2007
Completion date August 2008
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06170060 - Treatment of Reflux With Sleeve Gastrectomy N/A
Not yet recruiting NCT06062225 - Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract After Proximal Gastrectomy N/A
Completed NCT01964131 - BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects Phase 1
Not yet recruiting NCT06056973 - Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis Phase 4
Recruiting NCT05899491 - Role of ARMA in Selective Subset of Refractory GERD Patients. N/A
Recruiting NCT01311908 - Incidence of Reflux Esophagitis After Pancreaticoduodenectomy N/A
Completed NCT03214081 - Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"
Not yet recruiting NCT01560598 - Adipokines and the Risk of Reflux Esophagitis N/A
Completed NCT00859287 - Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis N/A
Completed NCT00206180 - NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis Phase 4
Recruiting NCT04657848 - Preliminary Efficacy Analysis of Cheng's Giraffe Reconstruction After Proximal Gastrectomy N/A
Completed NCT02477475 - Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes N/A
Completed NCT03553563 - A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer Phase 3
Completed NCT01381991 - The Efficacy of i-Scan for Detecting Reflux Esophagitis N/A
Completed NCT04673643 - Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Reflux Esophagitis N/A
Recruiting NCT04531475 - Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis Phase 2
Completed NCT00586963 - Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis N/A
Completed NCT00634114 - Reflux Esophagitis Phase III Study (Maintenance Treatment) Phase 3
Completed NCT03388047 - Feasibility of Multi-Spectral Endoscopic Imaging for Detection of Early Neoplasia in Barrett's Oesophagus N/A
Recruiting NCT00154570 - 24 Hour Esophageal and Electrogastrography to Investigate the Mechanism of Reflux Esophagitis N/A